SYMBICORT offers something extra—sustained* control
with better breathing starting within 5 minutes each time1-3
SYMBICORT is NOT indicated for the relief of acute bronchospasm.
Mean percent change from baseline FEV1 was measured
at day of randomization, months 6 and 12.3
Majority of FEV1 improvement at 5 minutes each time†—
in a subset of SUN Study patients taking SYMBICORT 160/4.5 (n=121)4
Significant lung function improvement with continuous control,
as demonstrated over 12 months in the SUN Study (n=494)1,4
*Sustained improvement in lung function was demonstrated in a 12-month efficacy and safety study.
†In a serial spirometry subset of patients taking SYMBICORT 160/4.5 (n=121) in the SUN study, 67% of 1-hour postdose FEV1 improvement occurred at 5 minutes on day of randomization, 83% at month 6, and 84% at end of treatment.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.